Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
9366 | 1162 | 43.2 | 87% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
171 | 3 | MONASCUS//CITRININ//MONASCUS PURPUREUS | 58457 |
419 | 2 | STATINS//EZETIMIBE//SIMVASTATIN | 16502 |
9366 | 1 | PCSK9//PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9//ALIROCUMAB | 1162 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PCSK9 | authKW | 4863097 | 21% | 74% | 249 |
2 | PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 | authKW | 1917453 | 8% | 81% | 90 |
3 | ALIROCUMAB | authKW | 985360 | 4% | 83% | 45 |
4 | PCSK9 INHIBITORS | authKW | 583964 | 3% | 67% | 33 |
5 | EVOLOCUMAB | authKW | 493403 | 2% | 72% | 26 |
6 | PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 | authKW | 341597 | 1% | 100% | 13 |
7 | BIOCHEM NEUROENDOCRINOL | address | 286006 | 5% | 21% | 53 |
8 | PROPROTEIN CONVERTASE SUBTILISIN | authKW | 234091 | 1% | 64% | 14 |
9 | AMG 145 | authKW | 210213 | 1% | 100% | 8 |
10 | LOW DENSITY LIPOPROTEIN CHOLESTEROL | authKW | 209300 | 7% | 10% | 79 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Cardiac & Cardiovascular System | 8573 | 34% | 0% | 396 |
2 | Peripheral Vascular Diseases | 3867 | 17% | 0% | 202 |
3 | Medicine, General & Internal | 679 | 13% | 0% | 146 |
4 | Biochemistry & Molecular Biology | 472 | 20% | 0% | 238 |
5 | Pharmacology & Pharmacy | 335 | 12% | 0% | 143 |
6 | Endocrinology & Metabolism | 329 | 8% | 0% | 89 |
7 | Medicine, Research & Experimental | 100 | 5% | 0% | 54 |
8 | Hematology | 97 | 4% | 0% | 42 |
9 | Medical Laboratory Technology | 91 | 2% | 0% | 20 |
10 | Nutrition & Dietetics | 75 | 3% | 0% | 32 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | BIOCHEM NEUROENDOCRINOL | 286006 | 5% | 21% | 53 |
2 | CARBOHYDRATE LIPID METAB UNIT | 114430 | 1% | 31% | 14 |
3 | UNIT CARDIAC CARDIOVASC GENET | 88502 | 1% | 42% | 8 |
4 | HLTH POLICY QUAL INFORMAT PROGRAM | 80071 | 1% | 38% | 8 |
5 | DEV LAUNCH UNIT PCSK9 | 78830 | 0% | 100% | 3 |
6 | ENDOCRINOL METABCLIN | 78830 | 0% | 100% | 3 |
7 | DYSLIPIDEMIASTATE CARDIOVASC DIS | 77270 | 1% | 29% | 10 |
8 | SOC ITALIANA STUDIO ATEROSCLEROSI | 55637 | 1% | 35% | 6 |
9 | SECT CARDIOVASC | 54221 | 1% | 13% | 16 |
10 | BARBRA STREISAND WOMENS HEART HLTH PROGRAM | 52553 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL LIPIDOLOGY | 55273 | 3% | 6% | 37 |
2 | CURRENT OPINION IN LIPIDOLOGY | 15505 | 2% | 2% | 28 |
3 | ATHEROSCLEROSIS | 12776 | 6% | 1% | 72 |
4 | CURRENT ATHEROSCLEROSIS REPORTS | 8915 | 1% | 2% | 15 |
5 | CLINICAL LIPIDOLOGY | 6859 | 1% | 3% | 10 |
6 | JOURNAL OF LIPID RESEARCH | 5391 | 4% | 0% | 42 |
7 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 5038 | 1% | 2% | 9 |
8 | ATHEROSCLEROSIS SUPPLEMENTS | 4635 | 1% | 3% | 7 |
9 | LIPIDS IN HEALTH AND DISEASE | 3891 | 1% | 1% | 15 |
10 | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 3050 | 4% | 0% | 43 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SCHULZ, R , SCHLUTER, KD , LAUFS, U , (2015) MOLECULAR AND CELLULAR FUNCTION OF THE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9).BASIC RESEARCH IN CARDIOLOGY. VOL. 110. ISSUE 2. P. - | 166 | 95% | 10 |
2 | SEIDAH, NG , AWAN, Z , CHRETIEN, M , MBIKAY, M , (2014) PCSK9: A KEY MODULATOR OF CARDIOVASCULAR HEALTH.CIRCULATION RESEARCH. VOL. 114. ISSUE 6. P. 1022 -1036 | 104 | 79% | 92 |
3 | LAMBERT, G , SJOUKE, B , CHOQUE, B , KASTELEIN, JJP , HOVINGH, GK , (2012) THE PCSK9 DECADE.JOURNAL OF LIPID RESEARCH. VOL. 53. ISSUE 12. P. 2515 -2524 | 91 | 95% | 123 |
4 | BERGERON, N , PHAN, BAP , DING, YC , FONG, A , KRAUSS, RM , (2015) PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITION A NEW THERAPEUTIC MECHANISM FOR REDUCING CARDIOVASCULAR DISEASE RISK.CIRCULATION. VOL. 132. ISSUE 17. P. 1648 -1666 | 106 | 79% | 26 |
5 | ABIFADEL, M , ELBITAR, S , EL KHOURY, P , GHALEB, Y , CHEMALY, M , MOUSSALLI, ML , RABES, JP , VARRET, M , BOILEAU, C , (2014) LIVING THE PCSK9 ADVENTURE: FROM THE IDENTIFICATION OF A NEW GENE IN FAMILIAL HYPERCHOLESTEROLEMIA TOWARDS A POTENTIAL NEW CLASS OF ANTICHOLESTEROL DRUGS.CURRENT ATHEROSCLEROSIS REPORTS. VOL. 16. ISSUE 9. P. - | 107 | 93% | 24 |
6 | NORATA, GD , TIBOLLA, G , CATAPANO, AL , (2014) TARGETING PCSK9 FOR HYPERCHOLESTEROLEMIA.ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54. VOL. 54. ISSUE . P. 273-293 | 99 | 96% | 19 |
7 | LIPINSKI, MJ , BENEDETTO, U , ESCARCEGA, RO , BIONDI-ZOCCAI, G , LHERMUSIER, T , BAKER, NC , TORGUSON, R , BREWER, HB , WAKSMAN, R , (2016) THE IMPACT OF PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 SERINE PROTEASE INHIBITORS ON LIPID LEVELS AND OUTCOMES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIA: A NETWORK META-ANALYSIS.EUROPEAN HEART JOURNAL. VOL. 37. ISSUE 6. P. 536 -U103 | 36 | 86% | 38 |
8 | CARIOU, B , LE MAY, C , COSTET, P , (2011) CLINICAL ASPECTS OF PCSK9.ATHEROSCLEROSIS. VOL. 216. ISSUE 2. P. 258 -265 | 77 | 94% | 64 |
9 | NORATA, GD , TAVORI, H , PIRILLO, A , FAZIO, S , CATAPANO, AL , (2016) BIOLOGY OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9: BEYOND LOW-DENSITY LIPOPROTEIN CHOLESTEROL LOWERING.CARDIOVASCULAR RESEARCH. VOL. 112. ISSUE 1. P. 429 -442 | 94 | 68% | 3 |
10 | NORATA, GD , TIBOLLA, G , CATAPANO, AL , (2014) PCSK9 INHIBITION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA: PROMISES AND EMERGING CHALLENGES.VASCULAR PHARMACOLOGY. VOL. 62. ISSUE 2. P. 103 -111 | 77 | 90% | 14 |
Classes with closest relation at Level 1 |